Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the…

By N. Lindeman, P. Cagle, D. Aisner, M. Arcila, M. Beasley, E. Bernicker, Carol Colasacco, S. Dacic, F. Hirsch, K. Kerr and 12 more. Journal of Thoracic Oncology, 2018

922 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/cc75ed6cc084af95afffb38a0fa7bd643c03de80

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. (2021, background): “In at least two-thirds of patients who have advanced disease, testing is performed on the diagnostic core needle or cytology specimens.(37,38) For molecular testing, studies have reported comparable results in the overall failure rate, mutation rate, or mutation type for EGFR testing performed on bi”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, positive): “Recently, IHC has been accepted as an equivalent alternative to FISH for ALK testing [54].”